however, persistence of interseptovalvular space with the embryonic left venous valve remnant as the incomplete partition may explain the morphogenesis of the midline chamber. Because of marked asymmetry in the timing and sequence of events for pulmonary venous development, a process of differential pulmonary venous segregation, which supports the primary theory, 4 may explain right pulmonary vein malincorporation into the midline chamber.
B ilateral lung volume reduction (LVR) can significantly improve the functional capacity of selected patients with severe emphysema and an upper-lobe predominance of disease. 1, 2 However, because of its palliative nature, postoperative improvements usually peak within the first 6 months and slowly decline subsequently, eventually returning back to the baseline status in most patients. Little is known, however, as to whether redo LVR 3 can be reasonably proposed in selected patients after bilateral LVR.
Herein we describe 4 patients with upper-lobe prevailing emphysema who underwent completion lobectomy (CL) as a redo LVR after a previous bilateral operation. The patients, all men, were operated on between September 2001 and October 2002. All patients gave their written, informed consent. The mean interval between bilateral LVR and CL was 59 months. After the bilateral operation, marked improvements occurred in pulmonary function measures: ϩ360 mL in forced expiratory volume in 1 second (FEV 1 ), Ϫ1170 mL in residual volume, ϩ125 m in the 6-minute walking test, and ϩ5.25 mm Hg in arterial oxygen tension. Afterward, the FEV 1 annual decline averaged 0.23 Ϯ 0.09 L at 24 months and Ϯ0.08 L at 36 months.
CL was performed when FEV 1 returned to baseline values and high-resolution computed tomography showed severe emphysematous lung destruction that was prevailing in 1 upper lobe ( Figure  1,1 and 2) . Before CL, all patients were receiving maximized medical therapy and underwent a 4-week respiratory rehabilitation program.
CL (3 right upper lobectomies and 1 left upper lobectomy) was performed by video-assisted minithoracotomy (2 patients) or lateral thoracotomy (2 patients). In 2 instances, isolation of the hilar structures was accomplished in a standard manner. In another 2 patients, the fissure was not dissected free, and the upper lobe tissue was excised through nonbuttressed staple resection ( Figure  2 ). All patients were extubated in the operating room, but 1 required early reintubation and eventually died of respiratory failure. In the remaining 3 patients, there were no major complica- tions. The mean in-hospital stay was 11 days. Meaningful improvements occurred in all survivors 6 months after CL, as detailed in Table 1 . Right heart catheterization showed no significant changes in pulmonary artery pressure. So far, no patient is dead or mechanically ventilated. Severe osteoporosis developed in 1 patient because of prolonged steroid therapy. This is the first report dealing with redo LVR in patients with cigarette smoking-related severe emphysema and upper lobe predominance. Stammberger and coworkers 3 have already reported on a patient with ␣ 1 -antytripsin deficiency emphysema, who also benefited from redo LVR.
CL resulted in meaningful functional improvements in 3 of 4 patients, and in no instance did pulmonary hypertension, which can occur after bilateral LVR, 4 develop. Nonetheless, 1 patient died of respiratory failure after surgery. We believe that he probably had too-advanced disease in the remaining lung tissue, with a scarcely heterogeneous pattern of emphysema.
Anatomic resection is considered contraindicated in patients with emphysema because of the risk of removal of functioning lung tissue. However, lobectomy has been recently reported 5 as a successful LVR procedure in patients with severely emphysematous lung lobes. Despite the very limited cohort, our results suggest that in stringently selected patients with a completely destroyed and functionally useless residual upper lobe, CL can be followed by meaningful improvements in respiratory function measures and exercise capacity.
We advise that CL be strictly performed in patients who have already benefited meaningfully from the first reduction, because it is highly unlikely that a patient who did not benefit from LVR initially will improve after CL. We believe that one reliable way of monitoring the patient's condition is observing the FEV 1 decay. In fact, FEV 1 is a reliable measure of the severity of chronic obstructive pulmonary disease and is correlated with the clinical benefit of LVR. Our data suggest that FEV 1 decay is maximal between 12 and 24 months and becomes less steep subsequently. However, the unavoidable and sometimes accelerated functional decline observed after LVR emphasizes that more efforts must be devoted to improve the current surgical techniques.
We conclude that in carefully selected patients, CL can prolong the benefits of LVR, a surgical option that continues to stimulate active investigation and to raise concerns and skepticism but that can undoubtedly offer some hope to properly selected patients with severe emphysema. 
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